Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.21%
1,091.51
-2.30
-0.21%
—1,093.811,096.521,100.221,091.51——
SIXC
Communications
SIXC
Communications
SIXC
+0.22%
610.11
+1.34
+0.22%
—608.77608.77612.97608.77——
SIXE
Energy
SIXE
Energy
SIXE
-1.34%
1,237.98
-16.83
-1.34%
—1,254.811,253.011,253.871,226.33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.93%
1,744.71
-16.40
-0.93%
—1,761.111,764.271,766.881,744.71——
SIXM
Financials
SIXM
Financials
SIXM
-0.37%
640.18
-2.40
-0.37%
—642.58644.87648.48640.18——
SIXR
Staples
SIXR
Staples
SIXR
-0.18%
849.58
-1.55
-0.18%
—851.13855.66858.75845.56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.23%
217.48
-0.50
-0.23%
—217.98217.98218.65216.88——
SIXT
Technology
SIXT
Technology
SIXT
+1.52%
3,260.69
+48.86
+1.52%
—3,211.833,227.213,268.383,226.55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0.69%
942.45
-6.53
-0.69%
—948.98948.58957.83941.97——
SIXV
Health care
SIXV
Health care
SIXV
-0.52%
1,466.80
-7.72
-0.52%
—1,474.521,479.031,481.041,466.80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.22%
2,397.50
+5.38
+0.22%
—2,392.122,396.952,421.222,382.32——
Q1 2026 earnings • released • EPS beat +184.00% • Revenue beat +7.66%
See results
EBS:NYSE
Emergent Biosolutions Inc
$8.47
+2.92%
(+0.24) 1D
$8.42
-0.54% (-0.046)
After hours
Closed: May 1, 4:00:02 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EBS...
Open
$8.99
High
$9.32
Low
$7.53
Mkt. cap
437.43M
Volume
1.41M
P/E ratio
9.13
52-wk high
$14.06
52-wk low
$4.71
EPS
$0.93
Beta
2.35
Shares outstanding
51.64M
No. of employees
900
News stories
From sources across the web
Profile
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes. Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid. During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded. Wikipedia
About Emergent Biosolutions Inc
CEORobert G. Kramer Sr. | Joseph C. Papa
Employees900
FoundedSep 5, 1998
HeadquartersRockville, Maryland, United States
SectorBiotechnology
Websiteemergentbiosolutions.com
Last report
Apr 30, 2026
Fiscal Period
Q1 2026
Normalized EPS / Estimate
0.21/ (-0.25 est.)USD
+184.00%beat
Revenue / Estimate
156.10M/ (145.00M est.)USD
+7.66%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
140.90M
231.10M
148.70M
156.10M
Cost of goods sold
80.20M
99.00M
94.00M
72.00M
Cost of revenue
80.20M
99.00M
94.00M
-
Research and development expenses
-
200.00K
-600.00K
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
44.00M
28.30M
61.60M
-
Operating expense
60.20M
44.80M
77.30M
-
Total operating expenses
140.40M
143.80M
171.30M
-
Operating income
500.00K
87.30M
-22.60M
-
Other non operating income
-3.70M
-3.70M
-8.10M
-
EBT including unusual items
-16.80M
57.60M
-50.70M
-
EBT excluding unusual items
-17.90M
68.40M
-45.40M
13.40M
Income tax expense
-4.80M
6.40M
3.90M
-
Effective tax rate
28.57%
11.11%
-7.69%
49.25%
Other operating expenses
-
-
-
-
Net income
-12.00M
51.20M
-54.60M
-
Net profit margin
-8.52%
22.15%
-36.72%
-
Earnings per share
0.16
1.06
-0.43
0.21
Interest and investment income
-
-
-
-
Interest expense
-14.70M
-15.20M
-14.70M
-
Net interest expenses
-14.70M
-15.20M
-14.70M
-11.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
23.50M
110.30M
-100.00K
-
Gain or loss from assets sale
1.00M
2.20M
-11.20M
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer